Table 1

Baseline and clinical characteristics of patients in each disease cohort

VariablesnAMD (N=50)DMO (N=37)RVO (N=30)P value*
Baseline BCVA (ETDRS letters)55 (0–80)70 (0–80)55 (0–84)0.002†
Baseline CMT (μm)353.5 (199–794)352 (276–987)483.5 (263–763)0.007‡
Lens status (% Pseudophakic)544310<0.001§
Age (years)80 (61–98)71 (52–88)75 (45–90)<0.001¶
Male (%)5440430.414
Laterality of eye (% R)5457330.115
Hypertension (% positive)6492730.011**
Hyperlipidaemia (% positive)528643<0.001††
Smoker (%)7254500.091
Injection type
Bevacizumab (%)385457>0.05
Ranibizumab (%)8313>0.05
Aflibercept (%)1080>0.05
Mixed (%)443530>0.05
Diabetes duration (years)23 (2–50)
HbA1c (mg/dL)7.8 (5.9–12.1)
Laser at baseline (% positive)57
  • Data are presented as medians (range) for continuous data and proportions for categorical data.

  • *P values are global p values testing for a difference between any of the diseases. (Kruskal-Wallis for continuous variables or χ2/Fisher’s exact for categorical). For comparisons that are significant at the global level, adjusted pairwise p values for individual study comparisons are reported. Significant p values are bolded.

  • nAMD vs DMO p=0.002; DMO vs RVO p=0.020; nAMD vs RVO p=1.000.

  • ‡nAMD vs DMO p=1.000; DMO vs RVO p=0.027; nAMD vs RVO p=0.008.

  • §nAMD vs DMO p>0.05; DMO vs RVO p<0.05; nAMD vs RVO p<0.05.

  • nAMD vs DMO p<0.001; DMO vs RVO p=0.858; nAMD vs RVO p=0.005.

  • **nAMD vs DMO p<0.05; DMO vs RVO p>0.05; nAMD vs RVO p>0.05.

  • ††nAMD vs DMO p<0.05; DMO vs RVO p<0.05; nAMD vs RVO p>0.05.

  • BCVA, best-corrected visual acuity; CMT, central macular thickness; DMO, diabetic macular oedema; ETDRS, early treatment diabetic retinopathy study; Mixed, combination of either of the three injection types; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion.